HomeCompareJWCTF vs EPRT

JWCTF vs EPRT: Dividend Comparison 2026

JWCTF yields 651.47% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JWCTF wins by $503577.84M in total portfolio value
10 years
JWCTF
JWCTF
● Live price
651.47%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503577.90M
Annual income
$386,785,137,245.59
Full JWCTF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — JWCTF vs EPRT

📍 JWCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJWCTFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JWCTF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JWCTF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JWCTF
Annual income on $10K today (after 15% tax)
$55,374.59/yr
After 10yr DRIP, annual income (after tax)
$328,767,366,658.75/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, JWCTF beats the other by $328,767,355,744.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JWCTF + EPRT for your $10,000?

JWCTF: 50%EPRT: 50%
100% EPRT50/50100% JWCTF
Portfolio after 10yr
$251788.98M
Annual income
$193,392,575,043.15/yr
Blended yield
76.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

JWCTF
No analyst data
Altman Z
-9.3
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JWCTF buys
0
EPRT buys
0
No recent congressional trades found for JWCTF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJWCTFEPRT
Forward yield651.47%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$503577.90M$63.4K
Annual income after 10y$386,785,137,245.59$12,840.73
Total dividends collected$493990.56M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: JWCTF vs EPRT ($10,000, DRIP)

YearJWCTF PortfolioJWCTF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$75,847$65,146.58$11,205$505.18+$64.6KJWCTF
2$542,945$461,789.28$12,672$682.46+$530.3KJWCTF
3$3,670,393$3,089,441.65$14,490$930.48+$3.66MJWCTF
4$23,446,108$19,518,787.95$16,786$1,282.69+$23.43MJWCTF
5$141,614,527$116,527,191.03$19,753$1,791.56+$141.59MJWCTF
6$809,307,352$657,779,808.21$23,677$2,541.64+$809.28MJWCTF
7$4,379,155,354$3,513,196,486.95$29,008$3,672.99+$4379.13MJWCTF
8$22,451,936,399$17,766,240,170.59$36,463$5,425.08+$22451.90MJWCTF
9$109,152,115,265$85,128,543,318.27$47,238$8,221.57+$109152.07MJWCTF
10$503,577,900,579$386,785,137,245.59$63,385$12,840.73+$503577.84MJWCTF

JWCTF vs EPRT: Complete Analysis 2026

JWCTFStock

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Full JWCTF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this JWCTF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JWCTF vs SCHDJWCTF vs JEPIJWCTF vs OJWCTF vs KOJWCTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.